Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule containing oxycodone hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved. Oxycodone is a Schedule II controlled substance.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing oxycodone are listed in capsule, tablet and solution forms.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Oxycodone is a Schedule II opioid pain medicine that compounding pharmacies prepare as oral solutions, capsules and rectal suppositories by prescription only.
Oxycodone hydrochloride is a full opioid agonist, relatively selective for the mu-opioid receptor. By activating that receptor on nerve cells it closes calcium channels and opens potassium channels, lowering nerve excitability and changing how the brain and nervous system respond to pain. Manufactured single-ingredient products include Roxicodone immediate-release tablets (SpecGx), generic tablets, oxycodone oral solution (for example Hikma) and OxyContin extended-release tablets (KNOA Pharma). Roxicodone, generic tablets and oral solution are FDA-approved for pain severe enough to require an opioid analgesic when alternative treatments are inadequate, and OxyContin extended-release tablets are approved for severe and persistent pain that requires an opioid and cannot be adequately treated with alternatives, including immediate-release opioids; the labels say opioids should be reserved for patients whose alternatives do not work, are not tolerated or are otherwise inadequate. Prescribers may order oxycodone compounded when a patient needs a strength, liquid concentration, flavor-free or dye-free vehicle, or a rectal suppository that no manufacturer makes. Compounded preparations are not FDA-approved and require a prescription.
Oxycodone carries an FDA boxed warning covering addiction, abuse and misuse that can lead to overdose and death; life-threatening respiratory depression, especially when starting or increasing the dose; accidental ingestion, where a single dose can be fatal to a child; neonatal opioid withdrawal syndrome after prolonged use in pregnancy; the Opioid Analgesic REMS program; interactions with CYP3A4 inhibitors (such as erythromycin, ketoconazole, ritonavir) or stopping CYP3A4 inducers (rifampin, carbamazepine, phenytoin), which can raise oxycodone to fatal levels; and profound sedation, coma and death when combined with benzodiazepines, alcohol or other CNS depressants. Do not use it if you have significant respiratory depression, severe asthma in an unmonitored setting, or a known or suspected bowel obstruction. Do not take it within 14 days of an MAOI; serotonergic drugs raise the risk of serotonin syndrome, and buprenorphine or other mixed agonists can trigger withdrawal. Long-term use can cause adrenal insufficiency; do not stop suddenly after regular use. Oxycodone passes into breast milk; the label says typical immediate-release doses are unlikely to cause clinically relevant infant exposure but to watch for sedation and slowed breathing, while MedlinePlus advises not to breastfeed. Ask your prescriber or pharmacist about keeping naloxone or nalmefene on hand, and call 911 for an overdose even after giving it. Store it locked away from children.
Oxycodone is a mu-opioid agonist that inhibits adenylate cyclase, closes N-type calcium channels and opens potassium channels. Per the Roxicodone label, 60 to 87 percent of an oral dose reaches the systemic circulation, plasma protein binding is about 45 percent, and the apparent elimination half-life is 3.5 to 4 hours; Kinnunen et al. report CYP3A4/5 formation of noroxycodone (about 45 percent of a dose) and CYP2D6 formation of oxymorphone (about 19 percent), with about 10 percent excreted unchanged and a longer half-life in renal and hepatic impairment. Labeled indications are given above by product. A 2014 review of compounded preparations in outpatient hospice and palliative care (McNulty and Muller, IJPC), indexed under oxycodone and suppositories, covers pain and rectal pain. Dose, concentration and route are per prescriber. Monitoring: respiratory status at initiation and dose changes, sedation, signs of misuse, adrenal function with prolonged use, and reassessment when CYP3A4 modulators change. Oxycodone is a Schedule II controlled substance. Electronic prescribing of controlled substances is voluntary under federal DEA rules, CMS applies a prescriber-level threshold for Part D, and a number of states mandate it.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
